Parexel will incur restructuring costs of $30-$35 mil. beginning in the fourth quarter primarily due to consolidation or closure of U.S. sites. The move is expected to adversely affect near-term financial performance, and the company will issue revised earnings projections by the end of June...
You may also be interested in...
Keeping Track: Submissions Galore Start The New Year; US FDA Clears New Indications For Enhertu, Xalkori
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker
Vacci Prep is first “supplement to establish a standard of care for consumers when preparing their immune system for vaccinations,” Dentovations says.
Effective medical device regulation supports both safety and innovation needs. This article assesses how well the US FDA and the Australian TGA achieve this balance.